Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 1
1962 1
1963 2
1964 2
1966 2
1967 1
1968 1
1989 3
1994 2
1995 7
1996 2
1997 2
1999 1
2000 2
2001 3
2002 2
2003 2
2004 5
2005 1
2006 1
2007 2
2008 2
2009 5
2010 5
2011 4
2012 2
2013 3
2014 4
2015 2
2016 3
2017 3
2018 3
2019 4
2020 5
2021 16
2022 11
2023 11
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

120 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY; TENAYA and LUCERNE Investigators. Heier JS, et al. Lancet. 2022 Feb 19;399(10326):729-740. doi: 10.1016/S0140-6736(22)00010-1. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085502 Clinical Trial.
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, Pearce IA, Sakamoto T, Schlottmann PG, Silverman D, Sun JK, Wells JA, Willis JR, Tadayoni R; YOSEMITE and RHINE Investigators. Wykoff CC, et al. Lancet. 2022 Feb 19;399(10326):741-755. doi: 10.1016/S0140-6736(22)00018-6. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085503 Clinical Trial.
Reply.
Kokame GT, Fujimoto S. Kokame GT, et al. Ophthalmol Retina. 2023 Nov;7(11):e17-e18. doi: 10.1016/j.oret.2023.07.024. Epub 2023 Sep 1. Ophthalmol Retina. 2023. PMID: 37656101 No abstract available.
Reply.
Teo KYC, Kokame G, Sadda SR, Fujimoto S, Gomi F, Kim JE, Cheng MFS, Corradetti G, Amornpetchsathaporn A, Chainakul M, Lee WK, Lai TYY, Ruamviboonsuk P, Cheung CMG. Teo KYC, et al. Among authors: kokame g. Ophthalmol Retina. 2023 Jul;7(7):e10-e11. doi: 10.1016/j.oret.2023.03.013. Epub 2023 Apr 20. Ophthalmol Retina. 2023. PMID: 37086256 No abstract available.
Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial.
Khanani AM, Patel SS, Staurenghi G, Tadayoni R, Danzig CJ, Eichenbaum DA, Hsu J, Wykoff CC, Heier JS, Lally DR, Monés J, Nielsen JS, Sheth VS, Kaiser PK, Clark J, Zhu L, Patel H, Tang J, Desai D, Jaffe GJ; GATHER2 trial investigators. Khanani AM, et al. Lancet. 2023 Oct 21;402(10411):1449-1458. doi: 10.1016/S0140-6736(23)01583-0. Epub 2023 Sep 8. Lancet. 2023. PMID: 37696275
Polypoidal Choroidal Vasculopathy: Consensus Nomenclature and Non-Indocyanine Green Angiograph Diagnostic Criteria from the Asia-Pacific Ocular Imaging Society PCV Workgroup.
Cheung CMG, Lai TYY, Teo K, Ruamviboonsuk P, Chen SJ, Kim JE, Gomi F, Koh AH, Kokame G, Jordan-Yu JM, Corvi F, Invernizzi A, Ogura Y, Tan C, Mitchell P, Gupta V, Chhablani J, Chakravarthy U, Sadda SR, Wong TY, Staurenghi G, Lee WK. Cheung CMG, et al. Among authors: kokame g. Ophthalmology. 2021 Mar;128(3):443-452. doi: 10.1016/j.ophtha.2020.08.006. Epub 2020 Aug 11. Ophthalmology. 2021. PMID: 32795496 Free article.
Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.
Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, Ives JA, Jaffe GJ, Korobelnik JF, Lin H, Murata T, Ruamviboonsuk P, Schlottmann PG, Seres AI, Silverman D, Sun X, Tang Y, Wells JA, Yoon YH, Wykoff CC; YOSEMITE and RHINE Investigators. Wong TY, et al. Ophthalmology. 2023 Dec 28:S0161-6420(23)00933-8. doi: 10.1016/j.ophtha.2023.12.026. Online ahead of print. Ophthalmology. 2023. PMID: 38158159 Free article.
Reply.
Kokame GT. Kokame GT. Ophthalmol Retina. 2021 Dec;5(12):e43-e44. doi: 10.1016/j.oret.2021.09.004. Ophthalmol Retina. 2021. PMID: 34872710 No abstract available.
Reply.
Kokame GT, Fujimoto S. Kokame GT, et al. Ophthalmol Retina. 2024 Mar 9:S2468-6530(24)00064-2. doi: 10.1016/j.oret.2024.01.027. Online ahead of print. Ophthalmol Retina. 2024. PMID: 38466255 No abstract available.
Evolving treatment paradigms for PCV.
Fenner BJ, Cheung CMG, Sim SS, Lee WK, Staurenghi G, Lai TYY, Ruamviboonsuk P, Kokame G, Yanagi Y, Teo KYC. Fenner BJ, et al. Among authors: kokame g. Eye (Lond). 2022 Feb;36(2):257-265. doi: 10.1038/s41433-021-01688-7. Epub 2021 Jul 14. Eye (Lond). 2022. PMID: 34262165 Free PMC article. Review.
120 results